Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

oncolytic adenovirus expressing interferon YSCH-01

An oncolytic adenovirus that has been genetically engineered to express interferon (IFN), with potential immunostimulating and antineoplastic activities. Upon intratumoral administration, the oncolytic adenovirus expressing IFN YSCH-01 selectively infects and replicates in tumor cells, leading to tumor cell lysis. In addition, tumor cell lysis releases a variety of tumor-associated antigens (TAAs), which may potentially result in the activation of a systemic immune response against the TAAs-expressing tumor cells. The IFN expressed by the oncolytic adenovirus also activates T-lymphocytes, dendritic cells (DCs) and natural killer (NK) cells and induces an anti-tumor immune response against the tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:oncolytic adenovirus expressing IFN YSCH-01
oncolytic adenovirus YSCH-01
oncolytic virus YSCH-01
recombinant oncolytic adenovirus L-IFN YSCH-01
Code name:YSCH 01
YSCH-01
YSCH01
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search